Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.70 |
| ▸ | CA9 | Q16790 | 1/20 | 0.70 |
| ▸ | AR | P10275 | 9/20 | 0.68 |
| ▸ | PGR | P06401 | 1/20 | 0.64 |
| ▸ | TNF | P01375 | 1/20 | 0.64 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.64 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.64 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5373189 | 0.88 | MEN1 (0.77) | ARPGRTNFNOD2NOD1 | |
| SCHEMBL17847423 | 0.84 | ALDH1A1 (0.81) | CA12CA9MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL8752463 | 0.83 | CA12 (1.00) | CA12CA9MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL633327 | 0.81 | CA12 (0.83) | CA12CA9MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL19084640 | 0.81 | AR (0.76) | ARPGRMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3556110 | 0.79 | CA12 (0.60) | CA12CA9MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3555904 | 0.79 | WDR5 (0.64) | CA12CA9MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL5380382 | 0.78 | MEN1 (0.77) | ARPGRMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3552385 | 0.78 | CA12 (0.58) | CA12CA9MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL19329686 | 0.77 | MEN1 (0.69) | CA12CA9ARPGRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10195167-B2 | Compounds for use in the treatment of conditions associated with NADPH oxidase | GLUCOX BIOTECH AB (SE) | 2019-02-05 | — | — | US | claimed |
| US-20180271810-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH NADPH OXIDASE | GLUCOX BIOTECH AB (SE) | 2018-09-27 | — | — | US | claimed |
| CN-107405318-A | For treating the compound of the patient's condition related to nadph oxidase | 格卢科克斯生物科技有限公司 | 2017-11-28 | — | — | CN | claimed |
| EP-3233072-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH NADPH OXIDASE | Glucox Biotech AB (SE) | 2017-10-25 | — | — | EP | claimed |
| WO-2016096720-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH NADPH OXIDASE | GLUCOX BIOTECH AB (SE) | 2016-06-23 | — | — | WO | claimed |
| US-10195167-B2 | Compounds for use in the treatment of conditions associated with NADPH oxidase | GLUCOX BIOTECH AB (SE) | 2019-02-05 | — | — | US | disclosed |
| US-10195167-B2 | Compounds for use in the treatment of conditions associated with NADPH oxidase | GLUCOX BIOTECH AB (SE) | 2019-02-05 | — | — | US | disclosed |
| US-20180271810-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH NADPH OXIDASE | GLUCOX BIOTECH AB (SE) | 2018-09-27 | — | — | US | disclosed |
| CN-107405318-A | For treating the compound of the patient's condition related to nadph oxidase | 格卢科克斯生物科技有限公司 | 2017-11-28 | — | — | CN | disclosed |
| EP-3233072-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH NADPH OXIDASE | Glucox Biotech AB (SE) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016096720-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH NADPH OXIDASE | GLUCOX BIOTECH AB (SE) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016096720-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH NADPH OXIDASE | GLUCOX BIOTECH AB (SE) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180271810-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH NADPH OXIDASE | CYBB, NOX4, NOX1 | CA12 2451/4885CA9 2859/4885AR 4081/4885 |
| US-10195167-B2 | Compounds for use in the treatment of conditions associated with NADPH oxidase | CYBB, NOX4, NOX1 | CA12 2451/4885CA9 2859/4885AR 4081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.